Viewing Study NCT00113360

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:11 AM
Ignite Modification Date: 2026-02-25 @ 6:59 PM
Study NCT ID: NCT00113360
Status: COMPLETED
Last Update Posted: 2025-05-01
First Post: 2005-06-07
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Sponsor: M.D. Anderson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neuroendocrine Carcinoma View
None Islet Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Neuroendocrine Carcinoma View
None Low Grade Neuroendocrine Carcinoma View
None Neuroendocrine Carcinoid View
None Islet Cell Carcinoma View
None RAD001 View
None Everolimus View
None Octreotide Depot View
None Sandostatin LAR View
None Octreotide long-acting release (LAR) View
None Octreotide LAR View